Innova Biosciences introduces Thunder-Link PLUS
New improved antibody oligonucleotide conjugation kit.
Innova Biosciences has launched Thunder-Link PLUS, a new and improved version of the original Thunder-Link kit, enabling even faster and more efficient oligonucleotide conjugation.
The new kit offers all of the advantages of the original Thunder-Link technology, but now also works with antibody fragments and small proteins. Thunder-Link PLUS provides antibody and oligo activation in just 30 minutes, and oligo conjugation in only 1 hour, with no lengthy protocols. The kit enables excellent antibody and oligo recovery, with a robust and flexible clean-up procedure.
Fast, easy and efficient conjugation of oligonucleotides and antibodies has traditionally been a major obstacle when developing assays such as immuno-PCR, proximity extension assays, proximity ligation assays, and electrochemical proximity assays. Thunder-Link and now Thunder-Link PLUS are the easiest to use, fastest, most efficient and most effective oligonucleotide conjugation kits of their kind on the market.Dr Nick Gee, CEO of Innova Biosciences, commented: “Thunder-Link PLUS has been developed in response to discussions with Innova’s customer base, and represents a continuation of the company’s drive to be at the forefront of bioconjugation technology and innovation.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.